慢性肾脏病继发性甲旁亢治疗进展(综述)  

Progress in the treatment of chronic kidney disease secondary hyperparathyroidism

作　　者：李存枚[1] 李祖海[1] 白友为[1] 

机构地区：[1]安徽医科大学附属六安医院,安徽237005

出　　处：《安徽卫生职业技术学院学报》2015年第5期36-38,共3页Journal of Anhui Health Vocational & Technical College

摘　　要：继发性甲状旁腺功能亢进症(SHPT)是慢性肾脏病(CKD)常见的并发症。近年研究发现,新型的磷结合剂碳酸镧,能有效降低血清磷水平,并不引起继发骨损害和高钙血症,是一种相对较安全的磷结合剂,西那卡塞是被称为拟钙剂(calcimimetics)的新一类化合物中的第一个药物,能激活甲状旁腺中的钙受体,从而降低甲状旁腺素的分泌。尤其适用于慢性肾衰竭患者顽固性、继发性甲状旁腺功能亢进伴有高磷血症的短期治疗。Secondary hyperparathyroidism （SHPT） is a common complication of chronic kidney disease （CKD）. Recent studies have found that new phosphate binder lanthanum carbonate, can effectively reduce the level of serum phosphorus, do not cause secondary damage to the bone and hypercalcemia, are a relatively safe phosphate binders. Cinacalcet is known as the calcimimetic agent （calcimimetics） a new class of compounds in the first drug, can activate the parathyroid calcium receptor, thereby reducing the parathyroid hormone secretion. Especially for chronic renal failure patients with chronic renal failure, secondary Hyperthyroidism Accompanied by high levels of phosphorus in the short-term treatment.

关 键 词：高磷血症 碳酸镧 西那卡塞 

分 类 号：R692.5[医药卫生—泌尿科学]